Industries
- Life Sciences (MedTech, HealthTech, BioTech)
Technology
- AI
- Cloud Computing
- Data Analytics - Big Data
- Diagnostic/Imaging
- Software
Business Model
- B2B
- B2B2C
Revenue Model
- Licencing
- SaaS
- Subscription
Funding Sources
- Grant
- VC
About
e-NIOS was founded by a group of researchers with a long history of successful collaboration, who developed a novel, innovative methodology for biological knowledge mining, enabling the automation, acceleration and standardization of modern genomic applications, including precision/personalized medicine, drug discovery and biotechnology research. The methodology is implemented as a high-performance cloud application up to industry standards for scalable processing of big data.
Solution & Product
e-NIOS’ BioInfoMiner is a SaaS platform that enables data-driven, standardized analysis and interpretation of multi-omic data, offering an end-to-end streamlined solution, from raw multi-omic data to small sets of prioritized biomarkers (signatures), describing key molecular processes and their driver genes. Based on the signatures, BioInfoMiner features: 1. Identification of genomic drivers and key cellular/biochemical processes including drug target identification. 2. Pharmacogenomic analysis for drug targeting as well as drug repurposing or off label/repurposing trial use. 3. Sample and cohort/patient stratification for clinical trial design or meta-analysis.
Innovation & Scalability
The product is a cloud-based SaaS platform which scales directly with the available data. It enables automation of bioinformatic analytical workflows and interpretation of genomic data.
Traction & achievements
Company's clients and partners are prestigious universities, research centers and institutions from Europe and USA. The company has received several European Grants, including 3 Horizon 2020 and owns 3 international patents in co-ownership with the French national biomedical research institution INSERM.
Team & Why Us
Multidisciplinary team (biology, informatics, medicine) with a long history of successful collaboration in academic research.
Funding Needs
Series A for development of innovative Precision Medicine applications.
Fast, automated discovery of genomic and multi-omic biomarkers for Precision Medicine